Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)

This study has been completed.

Sponsor:

Information provided by:

Mutual Pharmaceutical Company, Inc.

ClinicalTrials.gov Identifier:

NCT00961116

First received: August 14, 2009

Last updated: October 27, 2009

Last verified: October 2009

History of Changes

Results First Received: August 24, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Bio-equivalence Study; Intervention Model: Crossover Assignment; Masking: Open Label; Primary Purpose: Basic Science
Condition:	Healthy
Interventions:	Drug: Fenofibric Acid (Fibricor™) 105 mg Tablet Drug: Fenofibrate (Tricor®) 145 mg Tablet

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Fifty-four (54) non-obese, non-smoking, healthy adult volunteers, consisting of members of the community-at-large, were enrolled.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Fenofibric Acid 105 mg Tablets Then Fenofibrate 145 mg Tablets	On the morning of Day 1 subjects received one tablet of the test formulation, fenofibric acid 105 mg after an overnight fast, followed by a 7 day washout period. On the morning of Day 8 subjects received one tablet of the reference formulation, fenofibrate 145 mg, after an overnight fast.
Fenofibrate 145 mg Tablets Then Fenofibric Acid 105 mg Tablets	On the morning of Day 1 subjects received one tablet of the reference, fenofibrate 145 mg after an overnight fast, followed by a 7 day washout period. On the morning of Day 8 subjects received one tablet of the test formulation, fenofibric acid 105 mg, after an overnight fast.

Participant Flow for 3 periods

Period 1: First Intervention

	Fenofibric Acid 105 mg Tablets Then Fenofibrate 145 mg Tablets	Fenofibrate 145 mg Tablets Then Fenofibric Acid 105 mg Tablets
STARTED	27	27
COMPLETED	27	27
NOT COMPLETED	0	0

Period 2: Washout Period of 7 Days

	Fenofibric Acid 105 mg Tablets Then Fenofibrate 145 mg Tablets	Fenofibrate 145 mg Tablets Then Fenofibric Acid 105 mg Tablets
STARTED	27	27
COMPLETED	25	24
NOT COMPLETED	2	3
Adverse Event	1	1
Withdrawal by Subject	1	1
Protocol Violation	0	1

Period 3: Second Intervention

	Fenofibric Acid 105 mg Tablets Then Fenofibrate 145 mg Tablets	Fenofibrate 145 mg Tablets Then Fenofibric Acid 105 mg Tablets
STARTED	25	24
COMPLETED	25	24
NOT COMPLETED	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Fenofibric Acid 105 mg Tablets and Fenofibrate 145 mg Tablets	All subjects received each of the two study regimens in a randomly assigned sequence of dosing periods. On the mornings of Day 1 and Day 8, each subject received one tablet of either fenofibric acid 105 mg or fenofibrate 145 mg following an overnight fast.

Baseline Measures

	Fenofibric Acid 105 mg Tablets and Fenofibrate 145 mg Tablets
Number of Participants [units: participants]	54
Age [units: participants]
<=18 years	0
Between 18 and 65 years	54
>=65 years	0
Age [units: years] Mean ± Standard Deviation	23.7 ± 5.5
Gender [units: participants]
Female	35
Male	19
Ethnicity (NIH/OMB) [units: participants]
Hispanic or Latino	0
Not Hispanic or Latino	54
Unknown or Not Reported	0
Race (NIH/OMB) [units: participants]
American Indian or Alaska Native	1
Asian	2
Native Hawaiian or Other Pacific Islander	0
Black or African American	1
White	48
More than one race	2
Unknown or Not Reported	0

Outcome Measures

Show All Outcome Measures

1. Primary:

Maximum Plasma Concentration (Cmax) [ Time Frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration. ]

Show Outcome Measure 1

2. Primary:

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] [ Time Frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration. ]

Show Outcome Measure 2

3. Primary:

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞) [ Time Frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration. ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Medical Director
Organization: Mutual Pharmaceutical Company, Inc.
phone: 215-697-1743
e-mail: clinicaltrials@urlmutual.com

No publications provided

Responsible Party:	Vice President, Branded products and Medical Affairs, Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov Identifier:	NCT00961116 History of Changes
Other Study ID Numbers:	MPC-028-07-1007
Study First Received:	August 14, 2009
Results First Received:	August 24, 2009
Last Updated:	October 27, 2009
Health Authority:	United States: Food and Drug Administration

To Top